Guided by Science.
Focused on Patients.
Driven by Results.
Gallop Oncology is a clinical-stage biotechnology company advancing a first-in-class, mutation-agnostic approach targeting galectin-9. We are initially focused on relapsed/refractory high-risk myelodysplastic syndromes, where there are no treatment options for the overwhelming majority of patients.
Leadership
Eric Elenko, PhD
Acting CEO of Gallop Oncology
Co-founder of PureTech Health
Aleksandra Filipovic, MD, PhD
Chief Medical Officer
Chris Korth
VP, Clinical Operations & Program Management
Advisors
Amer Zeidan, MBBS, MDhD
Division of Hematologic Malignancies, Yale Cancer Center
Andrew Brunner, MD
Harvard Medical School and Center for Leukemia at Massachusetts General Hospital
Brian Andrew Jonas, MD, PhD
Malignant Hematology/Cellular Therapy and Transplantation, UC Davis Comprehensive Cancer Center
Lionel Ades, MD, PhD
Hematology Department at Hôpital Saint-Louis, Université Paris Cité
Brian Ball, MD
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Eytan Stein, MD
Memorial Sloan Kettering Cancer Center
Steven Rosen, MD
NCI-Designated Comprehensive Cancer Center and Beckman Research Institute, City of Hope